China's Healthcare Reform
Interview with Ruilin Song, Executive President, China Pharmaceutical Research and Development Association (Part 2)
on June 20, 2010
(Interview in Chinese, with English subtitle. Translation by Rui Liu and Xiaoqi Chen, members of CABS.)
Mr. Ruilin Song is the Executive Director-General of Research Center for Medicinal Policy of Chinese Pharmaceutical Association, Executive President of China Pharmaceutical Research and Development Association, Chairman and Executive Editor of Chinese Journal of New Drugs, former Deputy Director-General of the Department of Education, Science, Culture and Public Health Legislative Affairs Office, the State Council of P.R. China.
Before 2008, Mr. Song mainly engaged in the legislative review and research of health and medicine. He participated in almost all of China's health legislation activities, which enabled him to become an expert on Chinese health and medicine legislation and law. In 2008, he returned to China from abroad to participate in the establishment of the Research Center for Medicinal Policy, Chinese Pharmaceutical Association and then made it to be a think-tank on medical policy, innovative medicine, essential drug and Pharmacoeconomics of the country.
Tags: CABS, BioPacific 2010, Song Ruilin, healthcare reform, China, China Pharmaceutical Research and Development Association, SinoPHRDA